StockData
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR) company profile

AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$3.96−0.16 (-3.88%)

Close on Nov 17, 2026Market cap $317.61MP/E –Yield –

About Atea Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing orally administered antiviral therapies for serious viral conditions. Utilizing a proprietary nucleos(t)ide platform, it designs candidate treatments targeting single-stranded ribonucleic acid viruses. Its leading pipeline asset is a combination regimen of bemnifosbuvir and ruzasvir, currently evaluated in late-stage clinical trials for treating hepatitis C virus infections across multiple genotypes. Additionally, the business is advancing AT-587, an oral antiviral candidate intended to treat chronic hepatitis E virus infections, specifically targeting immunocompromised patient populations who currently lack approved targeted therapeutic options.

The enterprise conducts its clinical development activities on an international scale, running late-stage clinical trial programs with sites located across the United States, Canada, and various countries outside of North America. Its global studies evaluate diverse geographic populations to encompass a broad array of viral genotypes. While the excerpt mentions company staff monitoring these multinational trials under the name Atea, the provided text does not disclose a specific headquarters location.

Summary of the business section of Atea Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Atea Pharmaceuticals, Inc.
Headquarters
Boston, MA
Address
225 Franklin Street, Suite 2100 02110
Phone
(857) 284-8891
Employees
55, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Massachusetts
Fiscal year ends
December 31
Auditor
KPMG LLP, Boston, Massachusetts

Stock & identifiers

Ticker
AVIR
Exchange
Nasdaq
IPO date
Oct 30, 2020
Shares outstanding
80M, Aug 10, 2026
Public float
$262.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1593899
CUSIP
04683R106
ISIN
US04683R1068
FIGI
BBG00TZNCJ75
Share class FIGI
BBG00TZNCJ84
EIN
46-0574869

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jean-Pierre SommadossiPresident, CEO, and Chairman, Director6,633,855
Andrea CorcoranSee Remarks823,576
Janet MJ HammondChief Development Officer127,665
Wayne FosterEVP, Chief Accounting Officer91,461
Maria Arantxa HorgaChief Medical Officer112,159
John VavrickaChief Commercial Officer176,672
Jerome M. AdamsDirector92,350
Arthur S. KirschDirector45,710
Howard BermanDirector–
Franklin M. BergerDirector536,097
Barbara Gayle DuncanDirector92,350
Bruno LucidiDirector142,350
Bruce PolskyDirector124,806
Polly A. MurphyDirector133,040

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.40M$3.60M$1.57M$9$125
FY2024$4.20M$4.30M$1.83M$8$93
FY2023$5.93M$3.40M$1.86M$7$94
FY2022$5.88M$705.20K$1.86M$12$90
FY2021$34.10M-$1.46M$8.02M$21$100
FY2020$2.89M$15.19M$2.93M$138$116

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
$703.49K$1.32M$962.37K$422.09K–$3.40M-19%
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal
$549.53K$442.17K$437.44K$247.29K$14.00K$1.69M-12%
Janet Hammond
Chief Development Officer
$590.89K$459.00K$437.44K$265.90K$14.00K$1.77M-18%
Maria Arantxa Horga
Chief Medical Officer
$523.64K$425.03K$421.69K$209.46K$14.00K$1.59M-14%
John Vavricka
Chief Commercial Officer
$443.17K$292.84K$290.46K$177.27K$14.00K$1.22M-12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 30, 2020
Offer price
$24.00
Securities offered
12,500,000
Gross proceeds
$300.00M
Exchange
Nasdaq
First trading day
Oct 30, 2020
First-day close
$30.34+26.4%
Lock-up ends (est.)
Apr 28, 2021

“The initial public offering price of our common stock is $24.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 4, 2026, we had 55 full-time employees, including 19 employees with M.D., Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?